Business & Economy · 44 views
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund.
Source excerpt retained from 2026-10-11.
Summary
By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Business & Economy
Continue reading recent Business & Economy coverage
- Poundland's future hangs in the balance as chain edges towards collapseContinue reading
- Oheka Castle, the 127-room Long Island estate that helped inspire 'The Great Gatsby,' has been sold. See inside.Continue reading
- ‘Fancy cars hold no appeal’: My wife and I have a 99% chance of outliving our savings. Why don’t we spend it all?Continue reading
- Business as a liberal art? Some high schools say yesContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow